Details for New Drug Application (NDA): 207970

✉ Email this page to a colleague

NDA 207970 describes CABAZITAXEL, which is a drug marketed by Accord Hlthcare, Actavis, Apotex, Breckenridge, Dr Reddys, and Mylan Labs Ltd, and is included in seven NDAs. Additional details are available on the CABAZITAXEL profile page.

The generic ingredient in CABAZITAXEL is cabazitaxel. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cabazitaxel profile page.

Summary for 207970

Tradename:	CABAZITAXEL
Applicant:	Actavis
Ingredient:	cabazitaxel
Patents:	0

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	SOLUTION;INTRAVENOUS			Strength	60MG/6ML (10MG/ML)
Approval Date:	Mar 14, 2024	TE:		RLD:	Yes

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.